Vol 6, Supplement 3 (May 26, 2017): Translational Cancer Research

Targeted therapy in small cell lung cancer: can DLL3 notch up a victory?

Jonathan M. Lehman, Leora Horn

PDF Pages: S453-S456 Full Text (6536) COI Form Open Access

Concomitant ALK/KRAS and ALK/EGFR mutations in non small cell lung cancer: different profile of response to target therapies

Federica Zito Marino, Andrea Ronchi, Marina Accardo, Renato Franco

PDF Pages: S457-S460 Full Text (7680) COI Form Open Access

Cognitive complaints in breast cancer patients treated with chemotherapy: a reality?

Marie Lange, Florence Joly

PDF Pages: S461-S463 Full Text (2753) COI Form Open Access

RIPK1-TRAF2 interplay on the TNF/NF-κB signaling, cell death, and cancer development in the liver

Satomi Yamamoto, Tomoo Iwakuma

PDF Pages: S464-S468 Full Text (6735) COI Form Open Access

New players in the Bruton’s tyrosine kinase vs. ibrutinib match

Stefania Fiorcari, Rossana Maffei, Roberto Marasca

PDF Pages: S469-S471 Full Text (1878) COI Form Open Access

Increased lipid desaturation and ovarian cancer stem cells

Thomas W. Grunt, Peter Valent

PDF Pages: S472-S475 Full Text (2752) COI Form Open Access

Long-term impact of staging breast magnetic resonance imaging—a risk for overtreatment?

Anne M. Kuritzky, Marie Catherine Lee

PDF Pages: S476-S478 Full Text (1736) COI Form Open Access

Portal vein tumor thrombus should not be considered as a contraindication for liver resection

Cheng-Qian Zhong, Xiu-Ping Zhang, Shu-Qun Cheng

PDF Pages: S479-S480 Full Text (2477) COI Form Open Access

Eastern experience: surgical resection may be the first choice of treatment for selected hepatocellular carcinoma patients with portal vein tumor thrombus

Xiu-Ping Zhang, Cheng-Qian Zhong, Shu-Qun Cheng

PDF Pages: S481-S485 Full Text (3034) COI Form Open Access

Vascular-targeted photodynamic therapy: a glimpse in the future of Urology?

Panagiotis Kallidonis, Evangelos N. Liatsikos

PDF Pages: S486-S488 Full Text (1849) COI Form Open Access

METLung: a disappointing result in a challenging patient population

Jeffrey Zweig, Heather Wakelee

PDF Pages: S489-S493 Full Text (2791) COI Form Open Access

Osimertinib for EGFR T790M positive non-small cell lung cancer—making it happen, turning good idea into great results

Tao Tao, Chunxia Su, Shengxiang Ren, Caicun Zhou

PDF Pages: S494-S497 Full Text (2159) COI Form Open Access

Characterizing advanced or metastatic adenocarcinoma of lung— one step closer?

Ka Man Cheung, James Chung Hang Chow, William Chi Shing Cho

PDF Pages: S498-S501 Full Text (3307) COI Form Open Access

Targeting Bruton’s tyrosine kinase expression levels through microRNAs in chronic lymphocytic leukemia treatment

Simar Pal Singh, Jasper Rip, Rudi W. Hendriks

PDF Pages: S502-S507 Full Text (3705) COI Form Open Access

Gefitinib in combination with pemetrexed in patients with advanced non-small cell lung cancer harboring EGFR mutations: is there any difference in acquired resistance mechanism between gefitinib monotherapy and the combination treatment?

Tatsuya Yoshida, Toyoaki Hida

PDF Pages: S508-S511 Full Text (2737) Open Access

Bacteriogenic magnetic nanoparticles as magnetic resonance imaging contrast agents

Dawen Zhao

PDF Pages: S512-S514 Full Text (2962) COI Form Open Access

What can we learn from 3 phase III trials of ASCEND-4: ceritinib vs. platinum/pemetrexed with pemetrexed maintenance, PROFILE 1004: crizotinib vs. platinum/pemetrexed, and J-ALEX: alectinib vs. crizotinib?

Nobuaki Ochi, Nagio Takigawa

PDF Pages: S515-S518 Full Text (4610) Open Access

Cancer therapy by targeting the Warburg effect with miR-143 and response monitoring with ¹⁸F-FDG PET

Kyung-Ho Jung, Kyung-Han Lee

PDF Pages: S519-S521 Full Text (2785) COI Form Open Access

Targeting angiogenesis in small cell lung cancer

Gerhard Hamilton, Barbara Rath

PDF Pages: S522-S528 Full Text (3658) COI Form Open Access

The pathogenesis of follicular lymphoma, beyond apoptosis resistance

Marcelo A. Navarrete, Pablo Oppezzo

PDF Pages: S529-S532 Full Text (3469) COI Form Open Access

Upfront radiation versus EGFR-TKI: which is the best approach for EGFR-mutated NSCLC patients with brain metastasis?

Francesco Passiglia, Christian Rolfo

PDF Pages: S533-S536 Full Text (3554) COI Form Open Access

Bevacizumab in extensive-disease small cell lung cancer: the search continues

Avyakta Kallam, Apar Kishor Ganti

PDF Pages: S537-S538 Full Text (2111) COI Form Open Access

Angiogenesis inhibitors for small cell lung cancer

Sang-Yun Song, Cheol-Kyu Park, In-Jae Oh, Young-Chul Kim

PDF Pages: S539-S540 Full Text (1582) COI Form Open Access

The success of NRG-GBM-RPA: biomarker-based classification, where to next?

Cheng-Chia Wu, Deborah R. Smith, Christine Chin, Tony J. C. Wang

PDF Pages: S541-S543 Full Text (2994) COI Form Open Access

Transarterial chemoembolization (TACE) combined with Sorafenib is more effective than TACE for hepatocellular carcinoma with portal vein tumor thrombus

Ze-Han Zhang, Hui-Min Zhu, Teng-Fei Zhou, Nan Li

PDF Pages: S544-S546 Full Text (2311) COI Form Open Access

Is it time to consider the sentinel lymph node mapping the new standard in endometrial cancer?

Andrea Papadia, Maria Luisa Gasparri, Michael D. Mueller

PDF Pages: S547-S552 Full Text (4046) COI Form Open Access

Harmonization of programmed cell death ligand-1 diagnostic assays in non-small cell lung cancer

Amy Popple, Timothy M. Illidge

PDF Pages: S553-S556 Full Text (3475) COI Form Open Access

Promising results from Checkmate 012: better patients or better immunotherapy?

Jaime Hunt, Maria A. Velez, Krikor Bornazyan, John Madrigal, James Carroll, Edward B. Garon

PDF Pages: S557-S559 Full Text (3138) COI Form Open Access

Improving the safety of associating liver partition and portal vein ligation for staged hepatectomy

Pål-Dag Line, Bjørn Atle Bjørnbeth

PDF Pages: S560-S563 Full Text (2598) COI Form Open Access

Aneuploidy meets network analysis: leveraging copy number alterations to identify molecular pathways disrupted in high-grade serous ovarian carcinomas

Yuchae Jung, Tae-Min Kim

PDF Pages: S564-S568 Full Text (2577) COI Form Open Access

RIPK1 and allies in the battle against hepatocyte apoptosis and liver cancer

Vangelis Kondylis

PDF Pages: S569-S577 Full Text (4308) COI Form Open Access

Branched chain amino acid metabolism and cancer: the importance of keeping things in context

Elizabeth M. Selwan, Aimee L. Edinger

PDF Pages: S578-S584 Full Text (10694) COI Form Open Access

Targeting cancer with tumor-specific therapeutic strategies—metabolic reprogramming beyond the Warburg effect

Paul Grippo, Ajay V. Maker

PDF Pages: S585-S586 Full Text (3590) COI Form Open Access

Commentary on “The MLL1-H3K4me3 axis-mediated PD-L1 expression and pancreatic cancer immune evasion”

Lori M. Minassian, Daniel Sanwalka, Charles H. Graham

PDF Pages: S587-S589 Full Text (2327) COI Form Open Access

Haploinsufficiency and mutation are two sides of the cancer coin as cause and therapeutics target

Qianqian Song, Wei Zhang, Yan Sun

PDF Pages: S590-S593 Full Text (3149) COI Form Open Access

Getting to know ovarian cancer spheroid: opportunity for spheroid-targeted therapy

Yuying Zhang, Lingli Long, Tiefeng Cao, Wang Min

PDF Pages: S594-S597 Full Text (3196) COI Form Open Access

Direct-acting antiviral treatment for hepatitis C in liver transplant candidates and recipients

Nobuhisa Akamatsu, Junichi Togashi, Kiyoshi Hasegawa, Norihiro Kokudo

PDF Pages: S598-S602 Full Text (2311) COI Form Open Access

STAT3: a crucial target for ovarian cancer stem cells that inhibits WNT signaling through a novel epigenetic mechanism

Mijung Kwon, Steven K. Libutti

PDF Pages: S603-S605 Full Text (3310) COI Form Open Access

Complement and disease: better no factor H than bad factor H

Paul N. Barlow

PDF Pages: S606-S609 Full Text (3790) COI Form Open Access

Osimertinib a new weapon in epidermal growth factor receptor-mutated non-small cell lung cancer patients

Antonio Rossi

PDF Pages: S610-S613 Full Text (2475) Open Access

Potential role of antiestrogens in treating ovarian cancer

Sumegha Mitra, Anirban K. Mitra

PDF Pages: S614-S616 Full Text (1964) COI Form Open Access

Ramucirumab efficacy in first-line gastric and esophageal cancer treatment

Federico Longo, Pablo Reguera, Alfredo Carrato

PDF Pages: S617-S621 Full Text (6276) COI Form Open Access

Fishing therapeutic T-cell receptors in healthy donor blood, is safety predictable?

Hakan Köksal, Sébastien Wälchli

PDF Pages: S622-S624 Full Text (2485) COI Form Open Access

Neoadjuvant versus definitive chemoradiation for locally advanced esophageal squamous cell carcinoma

Carl M. Post, Matthias F. Haefner, Chi Lin, Charles B. Simone II, Vivek Verma

PDF Pages: S625-S628 Full Text (3705) COI Form Open Access

Epigenetic mutations and cancer therapy Effectiven(EZH2)

Cristina Segovia, Jesús M. Paramio, Mónica Martínez-Fernández

PDF Pages: S629-S634 Full Text (5910) COI Form Open Access

The role of in-bore magnetic resonance imaging guided biopsy for the detection of clinically significant prostate cancer

Sunao Shoji

PDF Pages: S635-S636 Full Text (1688) COI Form Open Access

Editorial on combination treatment beyond sorafenib alone for hepatocellular carcinoma with portal vein tumor thrombosis

Sun Hyun Bae, Hee Chul Park

PDF Pages: S637-S642 Full Text (3125) COI Form Open Access

Ceritinib and cabozantinib: new tyrosine kinase inhibitors improve treatment options for non-small cell lung cancer patients

Santiago Viteri, Rafael Rosell

PDF Pages: S643-S646 Full Text (2826) COI Form Open Access

How upfront can we be about upfront therapy for brain metastases in patients with activating epidermal growth factor receptor mutation?

Dae Ho Lee

PDF Pages: S647-S649 Full Text (1744) Open Access

Vol 6, Supplement 3 (May 26, 2017): Translational Cancer Research

Editorial

Letter to the Editor